United Kingdom

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

24 Jun 2019
Change (% chg)

$-0.62 (-5.66%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Fuchs, Charles 

Dr. Charles S. Fuchs, M.D., MPH serves as Director of the Company. Fuchs has served as a member of our board of directors since October 2017. Dr. Fuchs has been the Richard Sackler and Jonathan Sackler Professor of Medicine, Director of the Yale Cancer Center and Physician-in-Chief of the Smilow Cancer Hospital since January 2017. He was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute from July 2007 to December 2016. Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident, and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health. We believe that Dr. Fuchs is qualified to serve on our board of directors due to his deep medical experience and service on the boards of directors of several cancer centers.

Basic Compensation

Total Annual Compensation, USD 6,658
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 322,885
Fiscal Year Total, USD 329,543

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --